Amniotics AB (OSTO:AMNI) Debt-to-Asset : 0.10 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Amniotics AB Debt-to-Asset?

Amniotics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr2.58 Mil. Amniotics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Amniotics AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was kr26.09 Mil. Amniotics AB's debt to asset for the quarter that ended in Dec. 2023 was 0.10.

Amniotics AB Debt-to-Asset Historical Data

The historical data trend for Amniotics AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amniotics AB Debt-to-Asset Chart

Amniotics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.03

0.01

0.52

0.10

Amniotics AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial										-	0.52	-	-	0.10

Competitive Comparison of Amniotics AB's Debt-to-Asset

For the Biotechnology subindustry, Amniotics AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amniotics AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amniotics AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Amniotics AB's Debt-to-Asset falls into.

Amniotics AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Amniotics AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.58	+	0)	/	26.086
	=	0.10

Amniotics AB's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.58	+	0)	/	26.086
	=	0.10

Amniotics AB (OSTO:AMNI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Amniotics AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Amniotics AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Amniotics AB (OSTO:AMNI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amniotics AB (OSTO:AMNI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

66J:Germany

Address

Scheelevagen 2, Lund, SWE, 223 63

Website

https://www.amniotics.com

Amniotics AB is a biopharma company focusing on mesenchymal stem cells from amniotic fluid. It provides a novel platform for the production of medically superior mesenchymal stem cells including ethical and medically sound bio-banking opportunities for the newborn.